Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Calidi Biotherapeutics ( (CLDI) ) has shared an announcement.
On July 9, 2025, Calidi Biotherapeutics entered into an inducement offer letter agreement with holders of various series of warrants, resulting in the exercise of warrants to purchase 6,595,000 shares of common stock at a reduced price. This transaction is expected to generate approximately $4.6 million in gross proceeds, which the company plans to use for advancing clinical and pre-clinical programs, operating expenses, and working capital. Ladenburg Thalmann & Co, Inc. acted as the placement agent for the transaction, which is anticipated to close on July 10, 2025. The company also agreed to issue new unregistered warrants as part of the inducement, with plans to file a registration statement for the resale of shares underlying these new warrants.
The most recent analyst rating on (CLDI) stock is a Buy with a $2.50 price target. To see the full list of analyst forecasts on Calidi Biotherapeutics stock, see the CLDI Stock Forecast page.
Spark’s Take on CLDI Stock
According to Spark, TipRanks’ AI Analyst, CLDI is a Underperform.
Calidi Biotherapeutics’ overall stock score reflects significant financial and technical challenges, typical of a developing biotech company. While corporate events bring positive leadership changes and strategic advancements, the company’s lack of revenue, high leverage, and bearish technical indicators weigh heavily on its score.
To see Spark’s full report on CLDI stock, click here.
More about Calidi Biotherapeutics
Calidi Biotherapeutics is a clinical-stage biotechnology company based in San Diego, California. The company focuses on developing targeted therapies that deliver genetic medicines to disease sites, particularly in oncology. Their proprietary Redtail platform is designed to create viral vectors that evade immune detection, enabling effective delivery to tumor sites. Calidi’s lead candidate targets non-small cell lung cancer and ovarian cancer, among other tumors with high unmet medical needs.
Average Trading Volume: 11,895,526
Technical Sentiment Signal: Sell
Current Market Cap: $11.56M
For detailed information about CLDI stock, go to TipRanks’ Stock Analysis page.